Expression of multidrug resistance-associated proteins in paediatric soft tissue sarcomas before and after chemotherapy

ARIANNA CITTI^{1*}, RENATA BOLDRINI^{1*}, ALESSANDRO INSERRA², ANNA ALISI³, ROSANNA PESSOLANO⁴, ANGELA MASTRONUZZI⁴, ANGELICA ZIN⁵, LUIGI DE SIO⁴, ANGELO ROSOLEN⁵, FRANCO LOCATELLI^{4,6} and DORIANA FRUCI⁴

¹Pathology Department, ²Paediatric Surgery Department, ³Liver Unit, ⁴Paediatric Haematology/Oncology Department, IRCCS, Ospedale Pediatrico Bambino Gesù, Piazza S. Onofrio 4, I-00165 Rome; ⁵Pediatric Haematology/Oncology Department, University of Padova, Via Giustiniani 3, I-35128 Padova; ⁶University of Pavia, Corso Strada Nuova 65, I-27100 Pavia, Italy

DOI: 10.3892/ijo_xxxxxxx

1 Abstract. Expression of multidrug resistance (MDR) proteins 2 is thought to significantly contribute to the different biological/ 3 clinical behaviour of soft tissue sarcomas (STS) of various histological types and clinicopathological stages, as they are 4 5 responsible for active efflux of cytotoxic drugs from tumour 6 cells. We investigated the expression of 3 MDR proteins, i.e., 7 permeability glycoprotein 1 (P-gp), multidrug resistance-associated protein 1 (MRP1) and multidrug resistance 3 (MDR3), 8 9 in 43 STS specimens from newly-diagnosed paediatric patients, 10 31 with rhabdomyosarcoma (RMS) and 12 with non-RMS STS. 11 To assess the influence of chemotherapy on STS drug resis-12 tance, the number of MDR-associated protein-positive cells was 13 determined in 15 patients on both primary lesions before chemotherapy and on residual tumour after chemotherapy. At least one 14 15 of the MDR-associated proteins tested was detected in 84% of 16 primary untreated STS specimens. In these specimens, MRP1 was detected in a high percentage (70%) of the cases, followed 17 by MDR3 in 58% and P-gp in 44%. Many specimens showed 18 19 co-expression of two different MDR proteins. Interestingly,

E-mail: doriana.fruci@opbg.net

*Contributed equally

Abbreviations: STS, soft tissue sarcomas; MDR, multidrug resistance; RMS, rhabdomyosarcoma; ARMS, alveolar rhabdomyosarcoma; ERMS, embryonal rhabdomyosarcoma; CF, congenital fibrosarcomas; MPNST, malignant peripheral nerve sheath tumours; SS, synovial sarcomas; P-gp, permeability-glycoprotein 1; MRP1, multidrug resistance-associated protein 1; MDR3, multidrug resistance 3

Key words: soft tissue sarcomas, multidrug resistance, multidrug resistance-associated proteins, chemotherapy resistance, paediatric tumours

MDR3 was significantly associated with the presence of PAX3/ 20 21 PAX7-FKHR transcripts in RMS (p<0.05). Moreover, expression of MRP1 and MDR3 was significantly more frequent in 22 23 group III and IV tumours as compared with those of groups I and II (p<0.01). After chemotherapy MRP1, MDR3 and, to a lesser 24 extent, P-gp expression was found to be increased in most of 25 the samples. The frequent expression of these MDR-associated 26 proteins in primary tumour cells before chemotherapy and the 27 increase of their levels after chemotherapy, suggest that these 28 29 proteins play a pivotal role in conferring drug resistance and in producing therapy-induced differentiation on STS. 30

31

32

33

Introduction

Paediatric soft tissue sarcomas (STS) are a heterogeneous group 34 of malignant tumours that originate from various non-epithelial 35 tissues and account for 10% of all childhood tumours (1). 36 Rhabdomyosarcoma (RMS) is the most common paediatric STS 37 accounting for half of all STS cases (2), followed by congenital 38 39 fibrosarcomas (CF), malignant peripheral nerve sheath tumours (MPNST) and synovial sarcomas (SS). These paediatric malig-40 nant tumours significantly differ in their biological behaviour 41 and in their response to chemotherapy (3). 42

An important obstacle to be overcome for successful 43 treatment of paediatric STS is represented by pre-existent 44 or acquired resistance to both structurally and functionally 45 different chemotherapeutic agents (4-8). Multidrug resistance 46 (MDR) can be brought about through different mechanisms, 47 including enhanced expression of cellular transporters, reduced 48 drug uptake, modifications in detoxification processes, enhanced 49 DNA repair processes, down-regulation of drug targets, 50 changes in cell-cycle regulation and alterations in apoptotic 51 pathways (9). Best studied is the overexpression of a family of 52 membrane transporter proteins known as ATP-binding cassette 53 (ABC) transporters (10,11). These transporters decrease the 54 intracellular concentration of cytotoxic compounds by actively 55 pumping drugs out of cells. Permeability-glycoprotein 1 (P-gp) 56 and MDR-associated protein 1 (MRP1) are the best character-57 58 ized among ABC transporters in human (7,11), and are known to be associated with MDR and to exhibit a similar resistance 59 phenotype (12,13). Another MDR-associated protein, named 60

Correspondence to: Dr Doriana Fruci, Immuno-Oncology Laboratory, Department of Paediatric Haematology/Oncology, IRCCS, Ospedale Pediatrico Bambino Gesù, Piazza S. Onofrio 4, I-00165 Rome, Italy

MDR3, is a close homologue of P-gp, which is known to be overexpressed in drug-resistant tumour cells (14,15).

3 Expression of these MDR-associated proteins has been 4 demonstrated in various primary untreated tumours (16-22). 5 This suggests that MDR-associated genes may have a role in 6 primary drug resistance observed during first-line chemotherapy. 7 However, the role of MDR-associated proteins in the drug resis-8 tance acquired through chemotherapy and its correlation with 9 the extension and evolution of the disease has not been fully 10 investigated in paediatric STS.

11 Thus, the present work was carried out to examine the 12 expression of the MDR-related proteins, namely P-gp, MRP1 13 and MDR3, before and after chemotherapy, in different primary 14 paediatric STS (RMS, CF, MPNST and SS) by immunohisto-15 chemistry, and to correlate their expression levels with tumour 16 malignancy and the presence of fusion gene transcripts.

18 Patients and methods

20 Patients and specimens. All tumour specimens were obtained 21 from patients diagnosed from January 2001 to May 2011, at the 22 'Bambino Gesù' Children Hospital, Rome, Italy, after having 23 obtained informed parental consent and approval from the Ethics 24 Committee of the Institution. The surgical specimens were 25 processed for routine histological examination by fixation in 4% 26 phosphate-buffered formaldehyde for up to 18 h and subsequent embedding in paraffin (23). All specimens were examined by 27 haematoxylin and eosin staining with additional immunohis-28 29 tochemical staining. The clinical features of the patients are 30 detailed in Table I. Patients were classified according to the 31 European Paediatric Soft Tissue Sarcoma Study Group (EpSSG) 32 RMS-2005 for localized RMS, MMT-IV-89/91 or MMT-98 for metastatic RMS and EpSSG NRSTS 2005 for non-RMS. 33 34 Tumours were graded after initial surgery according to the 35 classification developed by the Intergroup Rhabdomyosarcoma Study (IRS)-IV system which includes the following 4 entities: 36 37 group I, completely excised tumours; group II, grossly resected tumours with microscopic residual disease and/or completely 38 39 excised positive regional lymph nodes; group III, gross residual 40 disease after incomplete resection or biopsy; group IV, distant metastases at onset (24). Patients were treated according to 41 42 the following protocols: AIEOP RMS96 for patients enrolled between 2001 and 2004 and EpSSG 2005 for patients enrolled 43 since 2005. 44

45

Specimens of untreated (naïve-primary) STS were obtained from 46 43 paediatric patients, 19 male and 24 female, of which 31 with 47 RMS (15 alveolar RMS, ARMS, and 16 embryonal RMS, ERMS), 48 6 with CF, 3 with MPNST and 3 with SS. Specimens of post-49 50 chemotherapy were available for 15 out of the 43 patients. The 51 distribution of histological types roughly reflected the general 52 incidence of STS (25). The mean age at diagnosis was 5.8 years 53 (standard deviation, 6.6 years; range, 8 days to 203.3 months). 54 Group distribution was as follows: 6 cases (13.9%) for group I; 55 6 cases (13.9%) for group II, 24 cases (55.8%) for group III, and 7 cases (16.3%) for group IV. Among group I tumours, there were 56 two ERMS, three CF and 1 SS. Group II tumours included two 57 58 ARMS, one ERMS, two MPNST and 1 SS. Group III tumours were 7 ARMS, 13 ERMS, 2 CF, one MPNST and 1 SS. Group IV 59 60 tumours were 6 ARMS and 1 CF.

RT-PCR and real-time RT-PCR. Samples were tested for pres-61 ence of specific fusion transcripts, i.e., PAX3/FKHR and PAX7/ 62 FKHR for RMS, ETV6-NTRK3 for CF and SYT-SSX for SS 63 by RT-PCR. The TRIzol reagent (Invitrogen, Milan, Italy) was 64 used to extract total RNA from frozen samples. One microgram 65 of total RNA from each specimen was reverse-transcribed by 66 67 using the SuperScript II Reverse Transcriptase (Invitrogen) and random hexamers. PCR amplification was performed by using 68 the BioTaq DNA polymerase (Bioline, London, UK) according to 69 the manufacturer's instructions. PCR reaction mixture contained 70 1.5 mM MgCl₂, 0.2 *u*M of each primer, 1X PCR buffer, 0.4 mM 71 of each dNTPs, 0.5 U of Taq polymerase, and 1 μ l of the RT 72 product in a final 20 μ l reaction volume. Primers and PCR 73 conditions for MyoD1, PAX3-FKHR, PAX7-FKHR (RMS) 74 (26), ETV6-NTRK3 (CF) (27) and SYT-SSX (SS) (28) were 75 previously published. In each sample, \u03b32-microglobulin expres-76 sion was concomitantly assessed as a control for presence of 77 78 amplifiable RNA and for efficiency of reverse transcription. PCR reaction products were electrophoresed through 2% agarose gels, 79 and their sizes were determined by comparative analysis with 80 81 DNA Marker VI (Roche, Milan, Italy). Results were confirmed in at least 2 independent reactions for each assay. 82

The absolutely RNA FFPE kit (Stratagene, Santa Clara, 83 CA) was used to extract total RNA from formalin-fixed 84 paraffin-embedded samples according to the manufacturer's 85 instructions. Briefly, three 10-mm slices were deparaffinized 86 with d-limonene, washed with ethanol 100, 90 and 70%, and 87 digested with proteinase-K at 55°C for 3-18 h. The lysate was 88 passed through a filter cartridge and RNA was eluted in 30 ml 89 elution buffer (10 mM Tris-HCl, pH 7.5). One microgram of total 90 91 RNA was reverse-transcribed to cDNA using SuperScript III Reverse Transcriptase (Invitrogen) and random hexamers. 92 Quantitative RT-PCR for detection of MyoD1, PAX3-FKHR 93 94 and PAX7-FKHR was performed on ABI PRISM 7000 (Applied Biosystems, Foster City, CA) by using Taq-Man technology. The 95 ABL gene was used as endogenous control. The primers and 96 probes used for PCR amplification were designed using Primer3 97 software and are presented in Table II. Amplification and detec-98 tion were performed with the following profile: 40 cycles with 99 2 min 50°C; 10 min 95°C; 15 sec 95°C; 1 min 60°C. Similarly, 100 RT-PCR analysis for CF and SS specimens was performed 101 102 using primers and PCR conditions described above.

Antibodies. The following monoclonal antibodies (mAb) were104used: mouse mAb JSB-1 and MRPm6, directed against P-gp105(1:50 dilution) and MRP1 (1:20 dilution), respectively, purchased106from Monosan (Uden, The Netherlands), and mouse mAb anti-107MDR3 (clone P3 II-26, 1:50 dilution) purchased from Millipore108(Milan, Italy).109

103

110

Immunohistochemical staining. Immunohistochemical staining 111 was performed according to the following protocol. Consecutive 112 sections of paraffin-embedded tissue blocks were cut at 3 μ m. 113 Deparaffinization and antigen retrieval were performed with 114 PT-link (Dako, Milan, Italy) in Tris/EDTA (pH 9.0) (Dako) for 115 15 min at 98°C. Sections were incubated with primary mAbs 116 for 45 min at room temperature. Staining was detected using 117 a biotinylated-secondary antibody (Dako) for 15 min at room 118 temperature, followed by incubation with streptavidin alkaline 119 phosphatase (Dako). Bound streptavidin was detected with Fast 120


1

2

17

Characteristics	ARMS	ERMS	CF	MPNST	S
No. of patients (n=43)	15	16	6	3	3
Age (years)					
≤10	10	7	5	0	2
>10	5	9	1	3	1
Gender					
Male (n=19)	6	7	2	2	2
Female (n=24)	9	9	4	1	1
Tumour size (cm)					
<5	7	5	4	0	2
≥5	8	11	2	3	1
Initial primary tumour site					
Genitourinary	3	11	0	0	(
Head and neck	3	2	1	0	(
Orbit	1	0	0	0	(
Extremity	4	1	2	1	1
Other	4	2	3	2	2
IRS group					
Ι	0	2	3	0	1
II	2	1	0	2	1
III	7	13	2	1	1
IV	6	0	1	0	(
Positive fusion transcript	8	0	2	-	3
Negative fusion transcript	7	16	0	-	0
Missing fusion transcript data	0	0	4	3	(
STS tumors were characterized for the profession of the profession	esence of specific fus	ion transcripts: i.e., PA	X3/FKHR and PAX	X7/FKHR for RMS, ET	V6-NTRK

Transcript		Sequence	Amplicon (bp
ABL	Forward	CAACACTGCTTCTGATGGCAA	92
	Reverse	CGGCCACCGTTGAATGAT	
	Probe	CAACACCCTGGCCGAGTTGGTTCAT FAM-TAMRA	
MyoD1	Forward	AGGCGCCTACTACAACGAGG	76
	Reverse	CAGGCAGTCTAGGCTCGACAC	
	Probe	GCCCAGCGAACCCAGGCCCGGGAA FAM-TAMRA	
PAX3-FKHR	Forward	TGAACCCCACCATTGGCAAT	67
	Reverse	CTGTGTAGGGACAGATTATGACGAA	
	Probe	TGGCCTCTCACCTCAGAATTCAATTCGT FAM-TAMRA	
PAX7-FKHR	Forward	GGTCAGCAACGGCCTGTCT	80
	Reverse	CATTCTGCACACGAATGAACTTG	00
	Probe	CTCAGGAATTCAATTCGTCATAATCTGTCCCTACA FAM-TAMRA	



and non-RMS patients before (pre) and after (post) chemotherapy. Arrowheads indicate MDR-expressing tumour cells; arrows indicate MDR-expressing endothelium of small intratumoral vessels. Original magnification x40. Scale bars, 30 µm.

Red chromogene substrate (Dako) and levamisole in the reac-tion mixture for 10 min at room temperature. All samples were counterstained with haematoxylin. Sections of normal liver were used as positive controls for P-gp and MDR3, and kidney tissue for MRP1.

Scoring of immunohistological staining. The expression of MDR-associated proteins was independently assessed by two pathologists without any knowledge of the clinical data. The expression of P-gp, MRP1 and MDR3 was semi-quantitatively assessed by estimating the proportion of positively stained tumour cells. According to previous studies (3,29), samples

were considered negative when the staining was seen for $\leq 5\%$ 109 of tumour cells. Score 0 was assigned to this negative staining. 110 Positive staining was categorised into: score 1 for 6-25% posi- 111 tive tumour cells, score 2 for 26-50% positive tumour cells, 112 score 3 for 51-75% positive tumour cells and score 4 for >75% 113 positive tumour cells.

Statistical analyses. Statistical analysis was carried out with 116 SPSS 12.0 for Windows software. Paired samples t-test was 117 applied to compare the mean level of expression of the different 118 MDR proteins within the same specimens. The Spearman's 119 rank test was used to quantify the correlation between expres- 120

sion of different MDR proteins. χ^2 test was used to analyse the

differences in MDR expression between histological types and
 clinicopathological groups. A two-tailed p<0.05 was consid-

4 ered to be statistically significant.

5 6

1

- Results
- 7
- 8 MDR-associated protein expression in untreated STS. In the 9 43 primary STS samples, all the 3 MDR-associated proteins 10 (MDR proteins hereafter) tested, i.e., MRP1, MDR3 and P-gp, were detected either on cellular membranes or in the cytoplasm. 11 12 In the cytoplasm, MDR protein staining showed a homogeneous 13 pattern or a predominantly granular and partially homoge-14 neous pattern, depending on the different histotypes (Fig. 1). 15 Interestingly, positive MDR staining was detected in vascular endothelial cells. 16
- 17 The expression levels, graded by a score from 1 to 4 (see also Patients and methods), of the 3 MDR proteins tested are 18 shown for samples from 43 pre-treated patients in Table IIIA. 19 20 Expression of MRP1, MDR3 and P-gp was found in 30 cases 21 (70%), 25 cases (58%) and 19 cases (44%), respectively. In this 22 group of STS samples, expression of MRP1 was significantly 23 (p<0.05) higher than that of MDR3 and P-gp. At least one of 24 three MDR proteins was detected in 36 of the 43 cases inves-25 tigated (84%). Expression of all three proteins was found in 26 13 cases (30%), whereas co-expression of MRP1 and MDR3, MDR3 and P-gp, and MRP1 and P-gp was found in 22 cases 27 (51%), 13 cases (30%) and 16 cases (37%), respectively. When 28 29 the semi-quantitative scores (score 0 and score 1 to 4) were anal-30 vsed, a significant correlation was found between MDR proteins. 31 MRP1 expression correlated with that of MDR3 (Spearman's 32 correlation coefficients 0.56; p<0.0001) and P-gp (Spearman's correlation coefficients 0.40, p<0.01) as well as expression of 33 34 MDR3 correlated with that of P-gp expression (Spearman's 35 correlation coefficient 0.31; p<0.05).

36

37 MDR-associated protein expression in untreated STS of different histological types. Expression of MDR proteins in RMS (ARMS 38 and ERMS) and non-RMS (CF, MPNST and SS) STS is illus-39 40 trated as histogram for each of MRP1, MDR3 and P-gp in Fig. 2. 41 RMS samples, consisting of 15 ARMS and 16 ERMS, repre-42 sent the largest group in this study. Among the 31 RMS samples, 43 22 (71%) were positive for MRP1, 55% were positive for MDR3 44 and 45% were positive for P-gp. P-gp expression did not differ 45 between ARMS and ERMS. In contrast, MRP1 and MDR3 expression were different in the RMS histological subtypes: 46 MRP1 and MDR3 were expressed in 12 (80%) and in 11 (73%) 47 ARMS cases, respectively, whereas ERMS expressed MRP1 in 48 49 10 cases (63%) and MDR3 in 6 cases (38%), respectively. Thus, 50 the frequency of expression of MDR3 was higher in ARMS than in ERMS (p<0.05). 51

Non-RMS samples, including 6 cases of CF, 3 cases of MPNST and 3 cases of SS, were characterized by high expression of both MRP1 and MDR3, the percentage of positive cases being 67% for both proteins. In all cases, the level of expression was scored 2 to 4. P-gp staining was detected in 42% of the samples, in all cases with score 3-4.

- 58
- MDR-associated protein expression in untreated STS in different
 clinicopathological groups. Expression of MDR proteins with

Table III.

A, MDR protein expression (score 1-4) in pre-treatment samples 62 of STSs from all 43 patients tested. 63

Score	MRP1	MDR3	P-gp
0	13	18	24
1	1	0	0
2	4	2	3
3	9	5	6
4	16	18	10

B, MDR protein expression (score 1-4) in pre- and post-treatment samples of STSs from 15 patients.

Score	Mł	MRP1		MDR3		P-gp	
	Pre	Post	Pre	Post	Pre	Post	
0	7	3	12	6	9	6	
1	1	0	0	0	0	0	
2	1	0	0	1	2	2	
3	2	3	1	2	2	1	
4	4	9	2	6	2	6	

Score $0, \leq 5\%$ positive tumour cells; score 1, 6-25% positive tumour cells; score 2, 26-50% positive tumour cells; score 3, 51-75% positive tumour cells; score 4, >75% positive tumour cells. STS, soft tissue sarcomas. MRP1, multidrug resistance-associated protein 1; MDR3, multidrug resistance protein 3, P-gp, P-glycoprotein. Percentage may not add up to 100% due to rounding of numbers.




Figure 2. Expression of MDR-associated proteins per histological type. RMS
group includes alveolar and embryonal RMS, whereas non-RMS group includes
congenital fibrosarcoma, synovial sarcoma and malignant peripheral nerve112
113
114sheath tumours.114

117

respect to clinicopathological group is shown in Table IV. MRP1 118 and MDR3 expression was significantly higher in high-risk 119 group III and IV tumours [23 cases (74%) and 20 cases (65%) 120

61

73

74

75

87

88

89

90

91

92

¹¹⁵ 116

before




Figure 3. Expression of MDR-associated proteins in primary STS tumours and in residual tumour after chemotherapy. Pairwise comparison of MRP1, MDR3 and P-gp expression in primary STS tumours and in residual tumour after chemotherapy.

after

before

respectively] as compared with low-risk group I and II tumours [7 cases (58%), 5 cases (42%), respectively] (p<0.01). P-gp was found in 8 cases (67%) of high-risk group III and IV tumours and 11 cases (35%) of low-risk groups I and II, respectively.

after

before

MRP1 and MDR3 were more frequently co-expressed in high-risk groups III and IV with respect to low-risk groups I and II (p=0.03), while MRP1 and P-gp or MDR3 and P-gp co-expression did not correlated with tumour group (not shown).

MDR-associated protein expression in untreated STS and their correlation with the presence of fusion transcripts. Most STS are characterized by the presence of chromosomal translocations, which results in the expression of different fusion transcripts, such as PAX3/PAX7-FKHR in RMS, ETV6-NTRK3 in CF and SYT-SSX in SS. All these translocations generate novel transcription factors that might inappropriately regulate the expression of unusual target genes or, possibly, have the ability to interact with other transcription factors to regulate expression of novel target genes. Thus, we investigated expression of MDR proteins in relation to the presence of PAX3/PAX7-FKHR fusion transcripts in RMS. The presence of PAX3/PAX7-FKHR fusion transcripts was significantly associated with MDR3 expression in RMS (Spearman's correlation coefficients 0.34, p<0.05). No correlation between the presence of fusion transcripts and MRP1 or P-gp was detected.

MDR-associated protein expression in STS after treatment in comparison with that before treatment: a pairwise comparison. A comparative study on pre and post-therapy specimens was carried out in 11 RMS and 4 non-RMS, including 2 CF and 2 MPNST, with the aim of studying the effect of chemotherapy on MDR protein expression.

after

As shown in Table IIIB, the frequency of MDR protein expression in these 15 patients increased from 53 to 80% for MRP1 (p<0.05), from 20 to 60% for MDR3 (p<0.05), and from 40 to 60% for P-gp (p<0.05). In particular, treatment did not affect MRP1 expression in 8 samples, while induced an increase of its level in the remaining 7 samples. MDR3 expres- 100 sion was negative in 12 cases and strongly positive (score 3 101 or 4) in 3 cases before treatment. After chemotherapy, a marked 102 increase of MDR3 expression, mostly score 4, was seen in 6 103 cases (Table IIIA and Fig. 3). P-gp was negative in 9 cases and 104 positive in the remaining 6 cases (score 2-4) before treatment. 105 P-gp expression remained unchanged in 7 cases, increased in 106 6 cases and decreased in 2 cases after chemotherapy. These 107 data indicate that chemotherapeutic treatment is followed by 108 an increased incidence and expression level of MDR proteins 109 in a large fraction of STS regardless of histological types. 110 Interestingly, MDR expression seems to be higher in better- 111 differentiated tumour cells (Fig. 1).

Discussion

IV

One of the most important causes of treatment failure in paedi- 116 atric cancers is the acquisition of MDR (9). Various mechanisms 117 are involved in clinical drug resistance, but best studied is 118 overexpression of MDR proteins, which leads to decreased 119 intracellular accumulation of cytotoxic drugs.

1 MDR protein expression has been studied in various primary 2 paediatric solid tumours (3,17,18,20,30-35). De Cremoux et al 3 investigated the clinical significance of mRNA expression level of MDR-associated genes in 29 advanced neuroblastoma 4 5 samples and showed that P-gp and MRP1 mRNA overexpression was present in 74 and 30% of cases, respectively (31). 6 7 Consistent with these findings, we found MDR proteins in a 8 high percentage of primary STS (84%). In particular, MRP1 0 expression was detected in the vast majority of primary STS 10 (70%), followed by MDR3 (58%) and P-gp (44%). Interestingly, positive MDR staining was detected also in vascular endothe-11 12 lial cells, this finding confirming the role of MDR proteins at 13 this level.

Komdeur and colleagues assessed the expression of P-gp and MRP1 in 45 untreated RMS tumour specimens from both paediatric and adult patients and found most samples extensively positive for P-gp and MRP1 (80 and 56% of cases, respectively) (20). We found that 60% of all STS displayed co-expression of at least two of the tested MDR proteins, suggesting the existence of common expressing-regulatory mechanisms.

21 The expression level of MDR proteins has been associated 22 with the prognosis of the disease. Indeed, Norris et al demon-23 strated that a poor prognosis was correlated with high-level 24 expression of MRP1 in primary neuroblastoma (18). Oda et al 25 reported correlation between the MRP1 mRNA and degree of 26 malignancy of STS (32). Nakaniski et al reported a correlation 27 between tumour grade and P-gp expression when comparing 28 high-grade tumours with low- and intermediate-grade STS 29 (33). Accordingly, our data indicate that expression of MRP1 30 and MDR3 correlates with an advanced tumour malignancy 31 and that these proteins are mainly co-expressed in the high-32 risk group as compared with low-risk group STS (not shown). 33 Resistance to chemotherapy may be due to protein-mediated 34 MDR mechanisms already present in tumour cells before treat-35 ment, but it is also possible that repeated courses of chemotherapy modulate the expression of MDR proteins reducing treatment 36

efficacy. Oue *et al* reported an increase of P-gp and MRP1
expression after chemotherapy in various paediatric tumours
(36). On the basis of these already available data, we analyzed
the expression of MDR proteins after chemotherapy. Our results
demonstrate that expression of MDR proteins was either induced
or significantly increased after chemotherapy in many tumour
samples (Fig. 3).

44 Our own data, as well as previously reported studies, support 45 the hypothesis that MDR proteins play a role in the clinical/ biological behaviour of paediatric sarcomas, both RMS and 46 47 non-RMS, which are often characterized by poor response to therapy. The expression levels of MDR proteins both at diagnosis 48 49 and during the course of chemotherapy treatment could repre-50 sent important information to predict patient's prognosis. In fact, 51 treated tumours that have acquired high levels of MDR proteins 52 could relapse on and become resistant to the same or other drugs 53 sharing similar mechanisms of resistance.

Two possible mechanisms may contribute to the increase in the expression of MDR proteins after chemotherapy: the clonal selection of MDR protein-expressing tumour cells and up-regulation of MDR proteins. In some cases, residual tumour cells showed a marked expression of MDR proteins after chemotherapy (Figs. 1 and 3). These results may indicate that chemosensitive tumour cells died, and only the residual tumour cells that express MDR proteins are clonally selected 61 after chemotherapy. It is plausible that other mechanisms may 62 contribute to the increased expression of MDR-associated 63 genes after chemotherapy. Norris et al demonstrated a strong 64 association between N-myc and MRP1 expression in vivo and 65 in a murine neuroblastoma model (18). Loss of p53 protein 66 67 function, frequently found in sarcomas, has been hypothesized to contribute to up-regulation of the MRP1 gene (37). Cocker 68 et al demonstrated that overexpression of MDM2, a negative 69 regulator of the p53 tumour suppressor, results in an increased 70 expression of MDR1 gene in RMS (38). However, it is also 71 possible that chromosomal aberrations typical of certain 72 STS variants could affect MDR expression. In this respect, 73 we found a significant correlation between the presence of 74 PAX3/PAX7-FKHR fusion transcript and MDR3 expression 75 in RMS. This finding may indicate that a hybrid gene associ-76 ated with tumour development can up-regulate the expression 77 of MDR-associated genes, thereby increasing the malignant 78 79 potential of the tumour.

Although the sample analyzed in this study is small and 80 heterogeneous, our data indicate that the expression of MRP1, 81 MDR3 and P-gp varies between different clinicopathological 82 groups of STS, and it is conceivable that this might contribute 83 to the differences observed in the response to chemotherapy of 84 patients with STS. Our findings suggest that protein-mediated 85 86 MDR in paediatric STS is a complex phenomenon that deserves further investigation in order to better understand how the 87 expression of MDR proteins might predict tumour response to 88 chemotherapeutic agents and, consequently the prognosis of the 89 disease. Furthermore, approaches aimed at overcoming drug 90 91 resistance of tumour cells through down-regulation of MDR proteins with small interfering RNA and pro-inflammatory 92 93 cytokines (39,40) could be explored in the future and lead to the 94 development of novel treatment strategies of paediatric STS.

Acknowledgements

This work was supported by the IG grant AIRC (Associazione98Italiana per la Ricerca sul Cancro) to D.F. and partly supported99by the special project 5x1000 from AIRC to F.L.100

References

- Jain S, Xu R, Prieto VG and Lee P: Molecular classification of soft 104 tissue sarcomas and its clinical applications. Int J Clin Exp Pathol 105 3: 416-428, 2010.
- Klunder JW, Komdeur R, van Der Graaf WT, *et al*: Expression of multidrug resistance-associated proteins in rhabdomyosarcomas before and after chemotherapy: the relationship between lung resistance-related protein (LRP) and differentiation. Hum Pathol 34: 150-155, 2003.
- 4. Colvin OM: Drug resistance in the treatment of sarcomas. Semin 112 Oncol 24: 580-591, 1997. 113
- Gerlach JH, Bell DR, Karakousis C, et al: P-glycoprotein in human sarcoma: evidence for multidrug resistance. J Clin Oncol 5: 1452-1460, 1987.
- Robert J: Multidrug resistance in oncology: diagnostic and therapeutic approaches. Eur J Clin Invest 29: 536-545, 1999.
- Yoshikawa M, Ito A, Ishikawa T and Ikegami Y: [Drug resistance mediated by ABC transporters]. Gan To Kagaku Ryoho 31: 1-6, 118 2004. 119
- Melguizo C, Prados J, Rama AR, *et al*: Multidrug resistance and rhabdomyosarcoma (Review). Oncol Rep 26: 755-761, 2011.

102 103

101

95

96

- 9. Baguley BC: Multiple drug resistance mechanisms in cancer. Mol Biotechnol 46: 308-316, 2010.
- Higgins CF: ABC transporters: from microorganisms to man. Annu Rev Cell Biol 8: 67-113, 1992. 10.
- Leonard GD, Fojo T and Bates SE: The role of ABC transporters 11 in clinical practice. Oncologist 8: 411-424, 2003.
- Gottesman MM, Pastan I and Ambudkar SV: P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 6: 610-617, 1996.
- 6 Cole SP and Deeley RG: Multidrug resistance mediated by the 13. 7 ATP-binding cassette transporter protein MRP. Bioessays 20: 8 931-940, 1998.
- 9 14. Nooter K, Sonneveld P, Janssen A, et al: Expression of the mdr3 gene in prolymphocytic leukemia: association with cyclosporin-10 A-induced increase in drug accumulation. Int J Cancer 45: 11 626-631, 1990.
- 12 15. Herweijer H, Sonneveld P, Baas F and Nooter K: Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and 13 chronic leukemias and association with stimulation of drug accu-14 mulation by cyclosporine. J Natl Cancer Inst 82: 1133-1140, 1990.
- 15 16. Norris MD, Burkhart CA, Marshall GM, Weiss WA and Haber M: Expression of N-myc and MRP genes and their rela-16 tionship to N-myc gene dosage and tumor formation in a murine 17 neuroblastoma model. Med Pediatr Oncol 35: 585-589, 2000
- 18 17. Shapiro DN, Sublett JE, Li B, Downing JR and Naeve CW: Fusion of PAX3 to a member of the forkhead family of transcrip-19 tion factors in human alveolar rhabdomyosarcoma. Cancer Res 20 53: 5108-5112, 1993.
- 21 18. Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL and Haber M: Expression of the gene for multidrug-resistance-22 associated protein and outcome in patients with neuroblastoma. 23 N Engl J Med 334: 231-238, 1996.
- 24 19. Warmann SW. Heitmann H. Teichmann B. et al: Effects of P-glycoprotein modulation on the chemotherapy of xenotrans-25 planted human hepatoblastoma. Pediatr Hematol Oncol 22: 26 73-386, 2005
- 27 20. Komdeur R, Klunder J, van der Graaf WT, et al: Multidrug resistance proteins in rhabdomyosarcomas: comparison between 28 children and adults. Cancer 97: 1999-2005, 2003.
- 29 21. Sola JE, Wojno KJ, Dooley W and Colombani PM: P-glycoprotein status of favorable-histology Wilms' tumor predicts treatment outcome. J Pediatr Surg 29: 1080-1084, 1994. 30 31
- 22. Komdeur R, Plaat BE, van der Graaf WT, et al: Expression of 32 multidrug resistance proteins, P-gp, MRP1 and LRP, in soft tissue 33 sarcomas analysed according to their histological type and grade. Eur J Cancer 39: 909-916, 2003. 34
- 23. Flens MJ, Zaman GJ, van der Valk P, et al: Tissue distribution 35 of the multidrug resistance protein. Am J Pathol 148: 1237-1247, 36 1996.
- 24. Crist WM, Anderson JR, Meza JL, et al: Intergroup rhabdomyo-37 sarcoma study-IV: results for patients with nonmetastatic disease. 38 J Clin Oncol 19: 3091-3102, 2001.
- 39 25. Orbach D, Rey A, Oberlin O, et al: Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the 40 International Society of Pediatric Oncology (SIOP) Malignant 41 Mesenchymal Tumor Committee. J Clin Oncol 23: 4363-4371, 42 2005.

- 26. Sartori F, Alaggio R, Zanazzo G, et al: Results of a prospective 61 minimal disseminated disease study in human rhabdomyosarcoma 62 using three different molecular markers. Cancer 106: 1766-1775, 63 2006
- 27. Argani P, Fritsch M, Kadkol SS, Schuster A, Beckwith JB and 64 Perlman EJ: Detection of the ETV6-NTRK3 chimeric RNA of 65 infantile fibrosarcoma/cellular congenital mesoblastic nephroma 66 in paraffin-embedded tissue: application to challenging pediatric renal stromal tumors. Mod Pathol 13: 29-36, 2000. 67
- 28. Nilsson G, Skytting B, Xie Y, et al: The SYT-SSX1 variant of 68 synovial sarcoma is associated with a high rate of tumor cell 69 proliferation and poor clinical outcome. Cancer Res 59: 3180-3184, 1999 70
- 29. Camassei FD, Ferlini C, Jenkner A, et al: Nephroblastoma. DNA 71 characteristics and their modifications induced by prenephrec-72 tomy chemotherapy: a cytofluorimetric study. Pediatr Pathol Mol Med 21: 15-23, 2002 73
- Chan HS, Thorner PS, Haddad G and Ling V: Immunohisto-74 chemical detection of P-glycoprotein: prognostic correlation in 75 soft tissue sarcoma of childhood. J Clin Oncol 8: 689-704, 1990.
- 31. De Cremoux P, Jourdan-Da-Silva N, Couturier J, et al: Role of 76 chemotherapy resistance genes in outcome of neuroblastoma. Pediatr Blood Cancer 48: 311-317, 2007.
- 78 32. Oda Y, Schneider-Stock R, Rys J, Gruchala A, Niezabitowski A and Roessner A: Reverse transcriptase-polymerase chain reaction 79 amplification of MDR1 gene expression in adult soft tissue 80 sarcomas. Diagn Mol Pathol 5: 98-106, 1996.
- 33. Nakanishi H, Myoui A, Ochi T and Aozasa K: P-glycoprotein 81 expression in soft-tissue sarcomas. J Cancer Res Clin Oncol 123: 82 352-356, 1997
- 83 34. Kuttesch JF, Parham DM, Luo X, et al: P-glycoprotein expres-84 sion at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma. J Clin Oncol 14: 85 886-900, 1996.
- 86 Gallego S, Llort A, Parareda A and Sanchez De Toledo J: Expression of multidrug resistance-1 and multidrug resistance-87 associated protein genes in pediatric rhabdomyosarcoma. Oncol 88 Rep 11: 179-183, 2004. 89
- 36. Oue T, Yoneda A, Uehara S, Yamanaka H and Fukuzawa M: 90 Increased expression of multidrug resistance-associated genes after chemotherapy in pediatric solid malignancies. J Pediatr Surg 91 44: 377-380, 2009. 92
- 37. Wang Q and Beck WT: Transcriptional suppression of multidrug 93 resistance-associated protein (MRP) gene expression by wild-type p53. Cancer Res 58: 5762-5769, 1998 94
- 38. Cocker HA, Hobbs SM, Tiffin N, Pritchard-Jones K, Pinkerton CR 95 and Kelland LR: High levels of the MDM2 oncogene in paediatric 96 rhabdomyosarcoma cell lines may confer multidrug resistance. Br J Cancer 85: 1746-1752, 2001. 97
- 39. Izquierdo M: Short interfering RNAs as a tool for cancer gene 98 therapy. Cancer Gene Ther 12: 217-227, 2005. 99
- 40. Ho EA and Piquette-Miller M: Regulation of multidrug resistance by pro-inflammatory cytokines. Curr Cancer Drug Targets 100 6: 295-311, 2006.

102

- 103 104
- 105
- 106
- 107
- 108 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
 - 118
 - 119
 - 120

1

2

3

4

5

43

44

45

46 47

48

49

50

51

52

53

54

55

56

57

58

59